1Grif K, Manfred P D, Pfaller K, et al. In vitro activity of fosfomycin in combination with various antistaphyloccal substances [J]. J Antimicrob Chemother , 2001,48: 209.
2Utsui Y, Ohya S, Magaribuchi T, et al. Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus [J]. Antimicrob Agents Chemother, 1986,30(6):917.
5Nabin K, Shrestha J, Tomford W. Fosfomycin: A review [J]. Infect Dis Clin Prac ,2001,10(5 ) :255.
6Del V O, Trincado P, Martin M T, et al. The prevalence of methicillin-resistant Staphylococcus aureus phagotype 95in the Hospitals vall d' Hebron of Barcelona [J]. Enferm Infecc Microbiol Clin,1999,17(10):498.
7Yoshida R, Kuwahara-Arai K, Baba T, et al. Physiological and molecular analysis of a mecA-negative Staphylococcus aureus clinical strain that expresses heterogeneous methicillin resistance [J]. J Antimicrob Chemoth, 2003,51:247.
8Robert D S, John S B. Evolving antimicrobial chemotherapy for Staphylococcus aureus infections [J]. Crit care Med,2001,29(Suppl 4) :N92.
9Watanabe T, Kanno M, Sobu K, et al. In vitro studies on the combined effects of arbekacin and fosfomycin on methicillin-resistant Staphylococcus aureus [ J ]. J Antibiot, 1995,48 (2): 284.
10Washida H, Watanabe H, Noguchi Y. Clinical studies and morphological response on ST-95 (fosfomycin) [J].Hinyokika Kiyo, 1991,37 (3): 321.
